Show simple item record

dc.contributor.authorSolberg, Ole Geir
dc.contributor.authorStavem, Knut
dc.contributor.authorRagnarsson, Asgrimur
dc.contributor.authorBeitnes, Jan Otto
dc.contributor.authorSkårdal, Rita
dc.contributor.authorSeljeflot, Ingebjørg
dc.contributor.authorUeland, Thor
dc.contributor.authorAukrust, Pål
dc.contributor.authorGullestad, Lars
dc.contributor.authorAaberge, Lars
dc.date.accessioned2020-01-31T14:27:59Z
dc.date.available2020-01-31T14:27:59Z
dc.date.issued2019-02-21
dc.description.abstract<i>Introduction</i> - Many women undergoing coronary angiography for chest pain have no or only minimal coronary artery disease (CAD). However, despite the lack of obstructive CAD, they still have an increased risk of major adverse cardiovascular events. Pleiotropic effects of statins may influence microvascular function, but if statins improve microvascular function in unselected chest pain patients is not well studied. This study assessed microvascular function by using the thermodilution‐derived test “the index of microvascular resistance” (IMR) with the aim of determining the (i) IMR level in women with chest pain and non‐obstructive CAD and if (ii) IMR is modified by high‐dose statin treatment in these patients. Additional objectives were to identify the influence of statins on the health status as assessed with generic health questionnaires and on biomarkers of endothelial activation.<p> <p><i>Materials and methods</i> - The study was a randomized, double‐blind, single‐center trial comparing 6 months of rosuvastatin treatment with placebo. In total, 66 women without obstructive CAD were included. Mean age was 52.7 years and 55.5 years in the placebo and rosuvastatin group, respectively. Microvascular function was assessed using the IMR, health status was assessed using the SF‐36 and EQ‐5D questionnaires, and biochemical values were assessed at baseline and 6 months later.<p> <p><i>Results and conclusions</i> - In the placebo group IMR was 14.6 (<i>SD</i> 5.7) at baseline and 14.4 (<i>SD</i> 6.5) at follow‐up. In the rosuvastatin group IMR was 16.5 (<i>SD</i> 7.5) at baseline and 14.2 (<i>SD</i> 5.8) at follow‐up. IMR did not differ significantly between the two study groups at follow‐up controlled for preintervention values. C‐reactive protein (CRP) was comparable between the groups at baseline, while at follow‐up CRP was significantly lower in the rosuvastatin group compared to placebo [0.6 (±0.5) mg/L vs. 2.6 (±3.0) mg/L; <i>p</i> = 0.002]. Whereas rosuvastatin treatment for 6 months attenuated CRP levels, it did not improve microvascular function as assessed by IMR (Clinical Trials.gov NCT 01582165, EUDRACT 2011‐002630‐39.3tcAZ).en_US
dc.descriptionThis is the pre-peer reviewed version of the following article: Solberg, O., Stavem, K., Ragnarsson, A., Beitnes, J., Skårdal, R., Seljeflot, I., ... Aaberge, L. (2019). Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double‐blind randomized study. <i>Catheterization and Cardiovascular Interventions, 94</i>(5), 660-668., which has been published in final form at <a href=https://doi.org/10.1002/ccd.28157> https://doi.org/10.1002/ccd.28157</a>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en_US
dc.identifier.citationSolberg OG, Stavem K, Ragnarsson A, Beitnes JO, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L, Aaberge L. Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and cardiovascular interventions. 2019;94(5):660-668en_US
dc.identifier.cristinIDFRIDAID 1757947
dc.identifier.doi10.1002/ccd.28157
dc.identifier.issn1522-1946
dc.identifier.issn1522-726X
dc.identifier.urihttps://hdl.handle.net/10037/17292
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalCatheterization and cardiovascular interventions
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2019 Wiley Periodicals, Inc.en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleIndex of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized studyen_US
dc.type.versionsubmittedVersion
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record